New England Journal of Medicine· 2016Q1

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Frederik Nevens, Pietro Andreoné, G. Mazzella, Simone I. Strasser et al.

1,112citations
Q1SCImago
2016year

Short summary

A 12-month trial found obeticholic acid significantly improved liver function markers in patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol, with 46-47% achieving treatment goals vs. 10% on placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hepatology

HepatologyMedicine